Janet Peper-Gabriel
Company: Pieris Pharmaceuticals
Job title: Associate Director, Translational Research
Seminars:
Transitioning Inhaled Preclinical Studies to the Clinic: Development of PRS-220, an Inhaled Anticalin Protein targeting CTGF/CCN2 for the Treatment of Lung Fibrosis 10:00 am
Highlighting benefits of local intervention via inhalation versus systemic administration of drugs Using inhaled Anticalin proteins as a novel class of biotherapeutics for respiratory disease Illuminating the development and preclinical characterization of PRS-220, a novel inhaled CTGF inhibitor, that is in clinical development for the treatment of lung fibrosisRead more
day: Day Two